The thought of implanting the chip in the human brain is enough to hesitate to entertain the most fanatical science fiction fans.
According to Futurism, the mind control interface is still a completely new technology in its early stages of development and we are not yet fully prepared to fully integrate the human brain with the computer. But in the meantime, a company hopes to help patients with stroke and spinal cord injury by non-surgical implantation of electroencephalography (EEG) machines.
The revolutionary technology being developed by Neuralink and other brain-computer interface (BCI) companies pioneered by the American serial entrepreneur Elon Musk will likely help improve human intelligence, memory and communication in the future. Although the technology is promising in practice, in fact, the idea of implanting the chip in the human brain is enough to hesitate to enrage the most fanatical science fiction fan.
Headquartered in Israel, brain technology startup BrainQ, is taking a less invasive approach that combines the human brain with technology. Instead of implants, BrainQ uses a non-surgical EEG machine that records the brain’s electronic activity. EEG has been used by other paralyzed patients and BrainQ hopes their technology will achieve similar goals and improve the lives of stroke and spinal cord injury patients.
However, the neuroscience company also faces considerable obstacles that need to be cleared before their technology is used in the medical field. First, the technology needs to successfully complete human clinical trials. It then needs FDA approval to be commercially available in the United States. Ultimately, the most difficult challenge for BrainQ will be to keep competing with other companies trying to create something similar to EEG-based technology.
While companies like NeuroLutions and NeuroPace will technically be BrainQ competitors, the latter seems to be a leader in the applications of patients with stroke and spinal cord injury. The company hopes the technology will be available in the U.S. market by 2020. After that, they will continue their efforts to separate BrainQ from other companies by developing a broader disease application.
Assaf Lifshitz, a BrainQ spokesman, said the company hopes to use the technology in the future to collect data, improve the symptoms of Alzheimer’s patients and help treat several childhood illnesses.
The timeline set by BrainQ may be reasonable as it relies on less invasive techniques (relative to brain implants) that may be much easier to obtain approval from the Food and Drug Administration than other BCI techniques . With the introduction of this technology, BrainQ hopes it will be able to gather more extensive and extensive data on the electronic activities of the human brain. In the future, these data may help to provide a more accurate assessment of the patient’s condition and thus help them achieve more effective treatment.